“I allowed myself to cry for the first time,” Moderna’s chief medical officer, Dr Tal Zaks, said of the vaccine, which also reported a 100 percent success rate in preventing severe Covid cases, with no major safety concerns.
“In the trial, we have already saved lives. Just imagine the impact then multiplied to the people who can get this vaccine.”
The news from Moderna comes less than two weeks after the Pfizer-BioNTech partnership announced its own vaccine candidate was 95 percent effective and also asked for fast-tracked approval.
We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authorization from the U.S. FDA & conditional approval from the EMA. Read more: https://t.co/90FbcVHdWN pic.twitter.com/36tpY0QeFl
— Moderna (@moderna_tx) November 30, 2020
US Health Secretary Alex Azar said the US Food and Drug Administration was expected to meet on 10 December to consider approving the Pfizer-BioNTech vaccine, with Moderna's to follow one week later.
The vaccines' progress offers hope to millions in the US and Europe, where a surge in second wave coronavirus infections has put hospitals under renewed strain.
- One in ten French admit escaping to their holiday homes during second lockdown
- Major Paris mosques stay closed due to 30-person limit under eased lockdown
France's health authority has said it wants any Covid-19 vaccination to be optional, in recommendations drawn up for the government.
Instead, it’s hoped that the vast majority of French will be persuaded to get the jab by information campaigns.
Trump advisor quits
In separate news, a controversial member of US President Donald Trump's coronavirus task force has resigned from his post.
Scott Atlas, who questioned the need for masks and lockdown measures during his four months as a special advisor, stepped down on Monday.
In a tweet, Atlas said he "always relied on the latest science and evidence without any political consideration or influence".
